255 related articles for article (PubMed ID: 33722933)
1. Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases.
Avouac A; Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Marignier R; Pelletier J; Audoin B
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33722933
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
Durozard P; Rico A; Boutiere C; Maarouf A; Lacroix R; Cointe S; Fritz S; Brunet C; Pelletier J; Marignier R; Audoin B
Ann Neurol; 2020 Feb; 87(2):256-266. PubMed ID: 31725931
[TBL] [Abstract][Full Text] [Related]
3. Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab.
Perriguey M; Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Durozard P; Pelletier J; Audoin B
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34815322
[TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
6. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
7. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.
López-Chiriboga AS; Majed M; Fryer J; Dubey D; McKeon A; Flanagan EP; Jitprapaikulsan J; Kothapalli N; Tillema JM; Chen J; Weinshenker B; Wingerchuk D; Sagen J; Gadoth A; Lennon VA; Keegan BM; Lucchinetti C; Pittock SJ
JAMA Neurol; 2018 Nov; 75(11):1355-1363. PubMed ID: 30014148
[TBL] [Abstract][Full Text] [Related]
8. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.
Hamid SHM; Whittam D; Saviour M; Alorainy A; Mutch K; Linaker S; Solomon T; Bhojak M; Woodhall M; Waters P; Appleton R; Duddy M; Jacob A
JAMA Neurol; 2018 Jan; 75(1):65-71. PubMed ID: 29131884
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
13. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
[TBL] [Abstract][Full Text] [Related]
15. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease.
Albassam F; Longoni G; Yea C; Wilbur C; Grover SA; Yeh EA
Dev Med Child Neurol; 2020 Mar; 62(3):390-395. PubMed ID: 31468511
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases.
Hyun JW; Woodhall MR; Kim SH; Jeong IH; Kong B; Kim G; Kim Y; Park MS; Irani SR; Waters P; Kim HJ
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):811-817. PubMed ID: 28684532
[TBL] [Abstract][Full Text] [Related]
20. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
